Washington, DC—(ENEWSPF)—January 9, 2015. Daiichi Sankyo Inc., a global pharmaceutical company with its U.S. headquarters in New Jersey, has agreed to pay the United States and state Medicaid programs $39 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce physicians to prescribe Daiichi drugs, including Azor, Benicar, Tribenzor and Welchol, the Justice Department announced today.
“The Anti-Kickback Statute prohibits payments intended to influence a physician’s ordering or prescribing…
